

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10533834	
	Filing Date		2005-10-27	
	First Named Inventor	Maria Benktzon		
	Art Unit	1625		
	Examiner Name	Robin Annette Hylton		
	Attorney Docket Number	133087.02001		

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6365602		2002-04-02	Bernstein et al.			
	2	6476077		2002-11-05	Bernstein			
	3	6586432		2003-07-01	Bernstein			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20060241142		2006-10-26	Bernstein et al.			
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	9807722	WO		1998-02-26	Pfizer		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10533834
Filing Date	2005-10-27
First Named Inventor	Maria Benktzon
Art Unit	1625
Examiner Name	Robin Annette Hylton
Attorney Docket Number	133087.02001

2	9639383	WO		1996-12-12	Schering Corp.		<input type="checkbox"/>
3	9825617	WO		1998-06-18	Merck & Co.		<input type="checkbox"/>
4	0428434	EP		1990-11-06	Sanofi SA		<input type="checkbox"/>
5	0474561	EP		1998-12-09	Sanofi SA		<input type="checkbox"/>
6	0515240	EP		1997-09-24	Sanofi		<input type="checkbox"/>
7	0559538	EP		1993-03-01	Sanofi		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Notice of copending applications.	<input type="checkbox"/>
	2	Gitlin et al., "Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches," J Clin Psych (1994) 55(9):406-413.	<input type="checkbox"/>
	3	Papp et al., "The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats," Behav Brain Res (2000) 115(1):19-23.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10533834
Filing Date	2005-10-27
First Named Inventor	Maria Benktzon
Art Unit	1625
Examiner Name	Robin Annette Hylton
Attorney Docket Number	133087.02001

4	Ryckmans et al., "First dual NK(1) antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants," Bioorg Med Chem Lett (2002) 12(2):261-264.	<input type="checkbox"/>
5	Santarelli et al., "Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function," Proc Nat Acad Sci (2001) 98(4):1912-1917.	<input type="checkbox"/>
6	Schroeder et al., "FLIPR: a new instrument for accurate, high throughput optical screening," J Biomolecular Screening (1996) 1(2):75-80.	<input type="checkbox"/>
7	Stevenson et al., "4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity," J Med Chem (1998) 41(23):4623-4635.	<input type="checkbox"/>
8	Bernstein et al., "Discovery of novel, orally active dual NK1/NK2 antagonists," Bioorganic and Medicinal Chemistry Letters (2001) 11(20):2769-2773.	<input type="checkbox"/>
9	Kenakin et al., "The ligand paradox between affinity and efficacy: can you be there and not make a difference?," TRENDS in Pharmacological Sciences (2002) 23(6):275-280.	<input type="checkbox"/>
10	Rosenzweig-Lipson et al., "Differentiating antidepressants of the future: efficacy and safety," Pharmacology & Therapeutics (2007) 113(1):134-153.	<input type="checkbox"/>
11	McLean "Do substance P and the NK1 receptor have a role in depression and anxiety?," Current Pharmaceutical Design (2005) 11(12):1529.	<input type="checkbox"/>
12	Office Action dated September 17, 2007 in copending application no. 10/539,140.	<input type="checkbox"/>
13	Final Office Action dated February 8, 2008 in copending application no. 10/539,140.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10533834
Filing Date	2005-10-27
First Named Inventor	Maria Benktzon
Art Unit	1625
Examiner Name	Robin Annette Hylton
Attorney Docket Number	133087.02001

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.